Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please realize the difference and differentiate between Margin Lending Rates and Margin Maintenance % Requirements.
They are also based on your particular account and are not brokerage-wide. The confusion, personal info matter and typical subsequent disruptive threads is what makes the margin topic, like options, generally off-topic on the board and better suited for a board for that purpose.
Read this stuff!
"But it's not even close to a sure thing. Many of the clinicians in the field would far prefer to see an improvement in function, Schenk adds, with practical evidence that patients are better able to care for themselves day to day, than in cognition, where there's likely to be less agreement on the significance of an observed improvement as "different parts of the brain do different things."
Our patient/caregivers want two more years of availability. A stability/improvement in function will be obvious-or-not in 2 years from start, much less 3, regardless of semantics. They'll halt that P3 faster than an iHop gal can cancel an order.
"If Lilly is successful in getting the FDA to significantly lower the bar on efficacy for Alzheimer's, that kind of move could have a major impact on a variety of programs, including drugs like gantenerumab, which failed for Roche, or crenezumab and possibly even Biogen's closely watched program for aducanumab."
I got chills reading that and thinking of the strategist Missling.
"since they will be the first to file after the negative readout of bapineuzumab in 2012."
We'll see about that!
§
Nice read George. Led me to this article, but none of my credentials would gain access. Trying hard not to become a neurochemist by the end of this but the science is fascinating.
http://www.ncbi.nlm.nih.gov/pubmed/16237316
McMagyar: Every once in-a-while one of you guys shows up and just lays down some pump-ass poetry. POTD!
§
Nice moves. Congrats CTIXers!§
What an excellent observation/explanation circa1762! About the same as suing a plaintiff (Ms Boenstich) who was not employed by the company at the time in question...if that is indeed the case. It's laughably stale.
The IP infringement suit against Anivax shows AVXL takes their legal responsibilities seriously. When the announcement is made of a couple 100k settlement (instead of wasteful counter suit) in this stockholder suit wee can thank the company for being legally prudent and pursuing, diligently, the business plan and medical mission.
It is no mystery that our company founders are business speculators. There is nothing wrong with a successful speculator. Wall St doesn't give that type much credence, but it's the money that does the talking.
Thanks to all who post info to the board. Fight nice.
§
I would think not. Nor would the company have. I consider the 2 year extension a supreme hint-play by Missling. I don't need to see the 12 week anymore, and I suspect it is being withheld due to a requested additional analysis of the data by a our suitor. I am confident enough to say the data release is not being delayed for a negative reason in any WSOF.
Sorry, you're wrong. This sucks and will get suckier. No bottom for 2+ years. No bottom in sight. Trips are coming most likely.
§
Could be. Nice to see the interest. It does seem to appear 'top billing' alongside the AD indication. Please keep track for the board if you will.
Very interested in PsychoGenics and the use of the McGill specimens.
http://www.psychogenics.com/pdf/McGill_R_Thy1_APP_RatModel_of_Alzheimer_Disease.pdf
http://www.psychogenics.com/alzheimer.html
From the PR, "Leader of the Rett syndrome Natural History Study, Alan Percy, MD, stated: “Given the strong clinical safety data profile of ANAVEX 2-73, it would be encouraging to explore the compound in patients with Rett syndrome, which is a very vulnerable patient population that in addition to its neurodevelopmental symptoms also experience a significant number of seizures.”"
Again, the safety profile comes into play. If A2-73 begins to look like aspirin for CNSDs...look out. Safe, daily dosing and tonic seizure protection would mean the world for these patients. Epilepsy is a disease of side effects. If you can prevent the seizures, you can manage the disease. That is huge. Our receptor targets are elusive, yet crucial. The mouse studies indicated 90% protection. That is nothing to scoff at, and we are heading for real-world studies with our heterodimer-specific signaling compounds.
"Therefore, these scientists said, drugs against it might be prone to side effects, and safety for chronic treatment in the elderly would have to be demonstrated with special care. Emphasizing the large therapeutic safety window (t)his compound had shown thus far, Fisher countered that future toxicology studies would test the safety of targeting the modulatory action of these two receptors."
http://www.alzforum.org/news/conference-coverage/zuers-alpha-beta-sigma-which-will-yield-new-ad-drug
§
Would a A2-73/Methelyne Blue formulation for AD be protected under this IP as 'cytoprotective and cytoregenerative activity against the cytodegenerative diseases' covering neurodegenerative diseases?
Any thoughts on the PLUS rejection response? I actually lol'd when I read it, it seemed so...elementary.
§
TauRx's Methylene Blue formulation suffered such bioavailability issues they had to reformulate it to try and make it work.
http://www.alzforum.org/therapeutics/rember-tm
TRx0237 is a TAI and works farther downstream than our compounds. It is certainly a direct competitor to Anavex in the race for the first AD treatment to be labeled 'disease modifying'.
Many of TRx023's supposed beneficial effects, including neuroprotection via mitochondrial antioxidant properties , if proven, would help bolster the case for A2-73's MOA.
"Looking for ways to prevent tau aggregation is definitely a viable path for drug discovery," said Rosa Sancho, head of research at the charity Alzheimer’s Research UK. If the drug turns out effective and safe, "for the field it would be incredible, there are no treatments at the moment and they are so desperately needed."
The most recent patent issued was last Tuesday!
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Wischik+claude&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PTXT
Positive sign indeed!
§
Then it would be advantageous to buy here below 5 as it will likely rise on Monday?
Did you miss this post?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121293904
I highly doubt the IP would be abandoned.
§
frrol's explanation sounds correct to me. Without trying to be pharmacologists, which we are not...right?
Seems a natural game of ping-pong with the USPTO. We have Dr Thomas slinging our paddle. Missling is astute, and hired a preeminently qualified attorney who, like others on the team, is likely excited about having the opportunity to prosecute Anavex's IP.
The patent seals the deal and it will all come together, well planned by management. This filing supports my theory of why the 12wd has not been released. Misslingstones
§
A response to the non-final rejection of the PLUS application has been filed.
03-17-2016 A... Amendment/Req. Reconsideration-After Non-Final Reject PROSECUTION 7
03-17-2016 N417 EFS Acknowledgment Receipt PROSECUTION 2
Seems to me they are saying it is not obvious because one of ordinary skill would presume two agonists would be combative, not complimentary...?
§
What's up with this Anavex stock?
http://www.christenseninstitute.org/defining-disruptive-innovation-in-clinical-trials/
The drug will be brought to market for the benefit of the patient. BP will not like that. They will pay for their POTP.
§
Might be buying, tho...§
Good 'ole-fashioned biotech beat-down!!!
The chords go C - D - Em - D - C - D
I don't play options. I convert to divy stocks. They pay the bills.
The corned beef is simmering. The March Stout comes out of the cellar. Happy St Patrick's Day to all!!!
§
ps- I'm not selling. GO SUCK AN EGG TUTES!
Haha! He did. Set to sell @ 5.06
4.50 looking like a good bottom. They've sold what they have to sell. 4.80 close and move up rest of week.
§
Who's emerging scientific evidence???
Many factors play into the success or failure of a drug. Your assertion that similar compounds from a DDP face a certain statistical rate of failure may be true, but one of the challenges CNS drugs face is the specificity of receptor ligands, which all the similar compounds differ markedly in.
When it is NOT a fact, it is WRONG!
Thank you. His grades come first, but I admit it is good learning for math, science and economics.
Looking for 4.42 on an opening dump
§
Excellent! You can almost hear the journalists typing! I bet we see a few positive pieces this week. Let's hope they don't confuse the compounds...or which exchange the stock trades on!
§
He has to set his own stops. He sold @ 4.92 and used a DT. Might get left in the dust!
I don't know if we'll see 4.80 tomorrow. The 5.20 level looks more in play. I wonder if tom agrees?
JB3729: Oh no! He's slipping! Hopefully, we won't be subject to the F-R rule going into P3
AVXL vs the other leading brands:
§
That is what I think too. A bombshell PR and 50% gap up is more likely than bad news and a plunge to $2.
Dr Fisher got Dr Cuello to test his compound in his lab. This man is the head of neurological sciences for the top-ranked university in Canada. Author of over 400 papers on the subject.
https://www.researchgate.net/profile/Augusto_Cuello
To look at the validation this company's pipeline is receiving and call it a scam is supremely laughable. Did anyone check for bash tweets today? I didn't bother.
The fact that we HAVEN'T disclosed a sacrificial dilutive partnership is more encouraging than knowing for sure we will settle for a $1B MC.
It will be too late when affiliate interests are disclosed.
§
Insty just took the 50K. What happened to shorty?
§
Although there is no formal presenting going on, they could announce attendance and just PR the data that day. It does look like a good place for the company to be. The 12 week update is being delayed for some reason, IMO. It is not because the data is bad...more likely it is overwhelmingly disruptive.
The hedgies are feeding the tutes. Have been for four weeks. The CEO is actually a masterful institutional provider. A few here on the board see it, most sit blindly through the low volume...afraid to trade.
§
Well my 12 year-old picked up 1400 freebies @ 4.65 this morning and his trading shares are on the block. $300 for him today is just fine!
§
The poster, titled "AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible disease-modifying properties in McGill-R-Thy1-APP rats," was presented at the 14(th) International Symposium on Advances in Alzheimer's Therapy (AAT) from March 9-12, 2016. The study examined the responses of ANAVEX 3-71 in aged transgenic McGill-R-Thy1-APP rats and wild-type rats dosed with 10 micrograms/kg/day ANAVEX 3-71. Both types of rats (12-14 months of age) were given either oral ANAVEX 3-71 or a placebo control for 4.5 months and then subjected to a washout period for five weeks. Following the washout, a number of cognitive tests were performed with the rats, now 18-20 months of age.
For a .5kg rat that = 5ug/day. That's .65mg/day for a 150lb human. Yeah, that's pretty potent. The cognitive preservation after a 5 week washout is stellar, and again the drug shows cognitive enhancement in the dosed WT group.
http://anavex.com/files/2016-03-14_AV3-71_AF710B-AD_Springfield_poster.pdf
§
I believe we will develop A3-71 in-house. The trial groundwork being carried out with A2-73 will provide, if successful, a framework to give guidance on the timeline of A3-71. Our patents on the compound cover treatment indications in Alzheimer's disease, Insulin resistance syndrome, type-2 diabetes, Parkinson's Disease, Lewy Body Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Lobar Degeneration until 2032.
It will not be waiting a moment more than necessary, I can assure you. The French Connection is strong ladat!
Speaking of Frontotemporal Lobar Degeneration...perhaps our Digital Biomarker partners are waiting to present the 12 week data at a forum appropriate for them?
http://www.alzforum.org/conference-calendar
Alzheimer's Disease-Related Dementias 2016 Summit
29 – 30 March 2016
Bethesda, Maryland
View conference website
Digital Biomarkers Conference
31 March – 01 April 2016
Bethesda, Maryland
https://meetings.ninds.nih.gov/Home/Index/11958
§
"According to Fisher, the compound is orally available with a safety margin of more than 50,000 times the minimally active dose. “Those are orders of magnitude more potent than donepezil and other agonists acting either on the M1 or the s-1 receptors, respectively,” Fisher said."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117194301
§
ANAVEX 3-71 = p<0.001 "completely reversed the deficit observed in transgenic rats"
"This study examined potential long-term effect of the compound following a five-week hiatus from dosing, which suggests the potential for disease modification -- something we have not often seen," said Professor Claudio Cuello
Extremely small, astonishingly potent, completely safe.
§
It all takes time and funding. We can tend to get years ahead of ourselves on the MB. Six months between announcing clinical interest and the next stage is not unusual. I think there is some undisclosed interest in the RETT Syndrome indication, as we have been hearing about "A2-73 in an undisclosed rare disease indication" for a while now. Again, it can take a long time for things to develop. "Planning blinded controlled Phase 2" has some support from somewhere!
They said Dose Response Analysis and that's what they presented. More of what I expected to see back in November, so one step at a time, I guess.
Dose response was strong:
"Low--High
dose
was
the
only
factor
that
was
sta,s,cally
significant
to
affect
MMSE--?
and
ERP--?
scores
with
MMSE--?
(p=0.0285)
and
ERP--?
(p=0.0168),
respec,vely"
You will notice the further comparison to the AIBL-AD study in an effort to quantify the results of A2-73 alone vs PLUS. Again the 12 to 24 week response is what will show A2-73 as either a marginal add-on to donepezil or a replacement therapy.
I think perhaps that the 12 week data is robust, and the details of PK/PD are being fully analyzed and presented so that there can be no doubt as to the cause-effect relationship when that efficacy data is released.
A two year dosing extension for these 32pts tells us plenty about the real-world results of the treatment, IMO. A few of these participants have been on the therapy for a year already and would have to have shown obvious results for the extended dosing to be granted.
I believe the FDA wanted to see further BA/DR/PK/PD analysis before approving the larger trial and it was suggested to delay any further efficacy data until this bio data was fully investigated.
I don't expect any big surprises Monday. Heavy buying on the bottom if they dump it down.
The results of a McGill-R-Thy1-APP study on A3-71 done by the university was presented. That is what I want to see. And did Dr Fisher speak? That is the subject of my email to IR.
Eight confirmed target indications disclosed on page 4, with an apparently strong interest in the RETT Syndrome indication. The preclinical studies in anxiety and depression likely refer to the subject of this PR:
http://www.anavex.com/?news=anavex-announces-report-expanding-opportunity-for-therapeutic-application-of-anavex-compounds
We are guided by the general research of Sigma-1/M receptor compounds.
Still time to present data before the end of the month and it doesn't necessarily need to be at an event. A 3-year P2a is much more than was hoped for there. i was wrong about getting 12 week data, and I certainly won't be expecting anything in the future that is not part of the PR announcement.
GLTA
§
Me too. Beer?
§
It would seem the very first trial enrollees requested an extension in July 2015 after their 26 weeks. Now it seems these same participants have requested, again, an extension at the end of their 52 weeks. They (and their caregivers) don't care about MMSE and ADAS-COG scores. They care about that helpless, confused state of mind known as dementia that engulfs them.
“While we remain focused on Alzheimer’s, the remarkably fast onset of clinical effect of ANAVEX 2-73 increases our options to potentially pursue additional indications for diseases characterized by working memory impairment and may enable clinical trials to be completed within shorter time frames.”
§
ed-